Psyence Biomedical Ltd. Common Shares Cash Flow Conversion Efficiency
Psyence Biomedical Ltd. Common Shares cash flow conversion efficiency. Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has a cash flow conversion efficiency ratio of 0.060x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-662.00) by net assets ($-10.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Psyence Biomedical Ltd. Common Shares (2022–2025)
Cash flow conversion efficiency of Psyence Biomedical Ltd. Common Shares from 2022 to 2025. This chart illustrates how Psyence Biomedical Ltd. Common Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Psyence Biomedical Ltd. Common Shares (PBM) stock price for real-time trading data and today's change.
Psyence Biomedical Ltd. Common Shares Cash Flow Conversion Ratio Explained
Psyence Biomedical Ltd. Common Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Psyence Biomedical Ltd. Common Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their cash flow conversion efficiency. Also see Psyence Biomedical Ltd. Common Shares (PBM) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Concurrent Technologies Plc
LSE:CNC
|
-0.053x |
|
hGears AG
XETRA:HGEA
|
-0.050x |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
-0.028x |
|
Monsenso AS
CO:MONSO
|
-0.251x |
|
Birddog Technology Ltd
AU:BDT
|
-0.302x |
|
CXApp Inc.
NASDAQ:CXAI
|
-0.124x |
|
Haffner Energy SA
PA:ALHAF
|
-0.330x |
|
NEOMETALS LTD SP.ADS/10
F:9R91
|
N/A |
Annual Cash Flow Conversion Efficiency for Psyence Biomedical Ltd. Common Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Psyence Biomedical Ltd. Common Shares from 2022 to 2025. Review Psyence Biomedical Ltd. Common Shares (PBM) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.72 Million | $-3.73 Million | -0.556x | -306.95% |
| 2024-03-31 | $-10.97 Million | $-2.95 Million | 0.268x | +12739.31% |
| 2023-03-31 | $244.66 Million | $-519.60K | -0.002x | +63.52% |
| 2022-03-31 | $239.84 Million | $-1.40 Million | -0.006x | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more